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Patients (pts) with HR-MM are in need of new strategies
for relapse prevention due to high risk of treatment failure.
AlloHCT is an attractive treatment that relies on graft-versus-
myeloma to control the disease. Reduced intensity condi-
tioning alloHCT is associated with low transplant-related
mortality (TRM), broadening this approach to patients with
MM. However, MM progression remains a frequent cause of
treatment failure. Maintenance therapy may potentially
improve outcomes. The primary objective of this study was
to determine the tolerability and safety of lenalidomide
maintenance (Len) for 1 year post-alloHCT in pts with HRMM
deﬁned as: relapsed after autologous HCT and/or plasma-
blastic morphology >2%, b2M  5.5 mg/L, hypodiploidy, del
13 by standard karyoptyping, t(4;14), t(14;16) or del 17p.
Patients who experienced >3 progressions prior to alloHCT,
progressed or relapsed after alloHCT, had grade 3 graft-
versus-host disease (GVHD), on >10 mg/day (d) prednisone,
or with fallen donor chimerism prior to Len were excluded.
The starting dose of Len was 10 mg/d for 21 of 28d per cycle
with monthly dose escalation by 5 mg increments to
a maximum of 25 mg/d. Dose reduction to 5 mg/d and 5 mg
on alternating days (qod) was allowed to control for toxicity.
Thirty patients who received reduced intensity conditioning
were enrolled, with a median age of 54 (range 38-68), 57%
achieved very good partial response (VGPR) or better prior to
Len, 40% had unrelated donors and 97% received peripheral
blood grafts. The median time from alloHCT to Len was 96d
(range 66-171). Among 29 evaluable patients, a total of 200
cycles were initiated and 177were completed, with 45% at 10
mg/d, 17% at 5 mg/d and 21% at 5 mg qod. 17% of patients
received >10 mg/d. 8 patients terminated maintenance
during the ﬁrst cycle, and 10 (34%) completed treatment.
Reasons for maintenance discontinuation were acute GVHD
(37%), MM progression (33%), neutropenia (10%), skin rash
(10%) and infection (10%). Grade 3-4 neutropenia was the
most common reason for lowering dose or interruptingcycles. Complete response (CR) was the best response of 55%
of pts, and 4 of 14 pts not in CR at the start of maintenance
achieved CR after 2-5 cycles. Cumulative incidence of MM
progression from start of maintenance was 28% (95% CI, 12-
48%), TRM was 3% (0-12%) and grades 3 acute GVHD was
17% (6-33%). 12-month probabilities of progression-free
(PFS) and overall survival from initiation of Len were 68%
(95% CI 46-83%) and 88% (95% CI 67-96%). Despite Len being
completed in only 34% of pts, this drug appears to be
generally well tolerated although dose reductions were
frequently required due to neutropenia. Lowering starting
doses and growth factor support should be considered when
using Len in this setting. Survival outcomes observed in this
study suggest a beneﬁt of maintenance therapy in pts with
HRMM after alloHCT.81
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Patients with lymphoid malignancies who relapse after
autologous hematopoietic cell transplantation (HCT) have
few curative treatment options. Allogeneic HCT using full
dose conditioning can cure selected patients but high non-
relapse mortality (NRM) limits its broad applicability. We
developed reduced intensity conditioning for allogeneic HCT
with total lymphoid irradiation and rabbit anti-thymocyte
globulin (TLI-ATG) that was safe, well tolerated, protected
against GVHD and allowed for retained graft-versus tumor
reactions. We report the outcomes of 47 consecutive patients
with lymphoid malignancies who relapsed after auto-HCT
and received TLI-ATG conditioning followed by the infusion
of G-mobilized allografts. Included were 29 (62%) patients at
high risk of relapse because the disease failed to achieve
remission with salvage therapy prior to TLI-ATG, 20 (43%)
patients with relapse within 18 months of their auto-HCT,
and 22 (47%) patients at high risk of developing GVHD due to
the lack of fully HLA-matched related donor. 26 patients had
B-cell NHL (diffuse large B-NHL (n¼19), mantle cell
lymphoma (n¼4) or other subtypes (n¼3)) all of whom
received prior rituximab, 6 patients had T cell NHL, and 15
had Hodgkin lymphoma. The TLI-ATG regimen was well
tolerated and 46 (98%) patients received their graft infusion
as an outpatient. The hospital readmission rate in the ﬁrst
100 days was 28% (n¼13). Only 13 (28%) and 4 (9%) patients
Table 1
Patient Characteristics HDT-ASCR n¼20 alloSCT n¼20
Median age in years (range) 51 (33-70) 55 (34-69)
Median number of previous
lines of therapy (range)
2 (2-4) 3 (2-7)
Chemosensitive 19/20 (95%) 20/20 (100%)
CR 8 7
PR 11 13
Median remission duration
(months) prior to
re-induction therapy
11.5 (0*-31) 5 (0*-12)
Remission duration  12 months
from re-induction therapy
11/20 (55%) 20/20 (100%)
* Denotes chemorefractory disease prior to re-induction.
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respectively, during the ﬁrst 30 days post HCT. Durable
chimerism was achieved in 45 (96%) patients. The cumula-
tive incidence of grade II-IV acute GVHD at day 100 was 12%
and extensive chronic GVHD at 1-yr was 36%. Non-relapse
mortality (NRM) at 3 years was 7%. The median follow up for
all patients was 1142 days and 1525 days (range; 365-3667)
for the 34 (72%) living patients. The 36-month probability of
progression free and overall survival (OS) was 40% and 79%
respectively. It is noteworthy that among the 23 patients
with progressive disease after TLI-ATG, 11 were returned to
durable (>1 year) complete remission without subsequent
relapse following a donor lymphocyte infusion or chemo-
radiotherapy. 13 patients died (relapse¼8 and other
causes¼5). Proportional hazards model showed improved
relapse free survival with higher CD3+ donor chimerism
(p¼0.01). We conclude that for patients with lymphoma
relapse after auto-HCT, allogeneic HCT from a sibling or
unrelated donor using TLI-ATG conditioning was a well
tolerated outpatient procedure, did not induce signiﬁcant
cytopenias and was associated with 3 year NRM of<10%. It is
unlikely that TLI-ATG conditioning itself provided long-term
lymphoma control in these heavily pre-treated patients, with
advanced disease. Rather the 79% 3-yr OS and the fact that
the majority of patients continue in durable CR suggest
retained graft antitumor reactions following TLI-ATG.82
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Introduction: Follicular lymphoma (FL) is an indolent non-
Hodgkin lymphoma characterized by high response rates
and long response duration(s) to therapy. In the relapsed/
refractory setting (rel/ref), high-dose therapy and autologous
stem cell rescue (HDT-ASCR) and non-myeloablative (NMA)
allogeneic stem cell transplantation (alloSCT) are deﬁnitive
therapies shown to provide long term disease free intervals.
To date, there remains an inherent difﬁculty in deciding the
appropriate consolidative transplant modality in rel/ref FL.
Therefore, we conducted an analysis of clinical features of FL
pts undergoing ﬁrst HDT-ASCR or alloSCT.
Methods: We retrospectively reviewed all pts with rel/ref FL
that proceeded to HDT-ASCR or NMA alloSCT at MSKCC
between 2006 and 2010. Chemosensitive disease was
deﬁned as a partial response (PR) or complete response (CR)
to the last treatment regimen prior to transplant by
computed tomography scans per IWG Criteria. Events were
deﬁned as progression of FL or death from any cause. Event-
free survival (EFS) and overall-survival (OS) were estimated
using Kaplan-Meier method.
Results: We identiﬁed 40 pts with rel/ref FL who had HDT-
ASCR (N¼20) or alloSCT (N¼20). Pts characteristics are out-
lined in the table below: The median follow-up for
survivors is 34 months. The estimated 3-year EFS and OS was60% and 62% with HDT-ASCR and 79% and 85% with alloSCT
respectively (p¼ns). FL pts with remission duration  12
months prior to re-induction therapy proceeding to con-
solidative HDT-ASCR had signiﬁcantly shorter EFS compared
to those pts with previous remission duration > 12 months
(P < 0.05, Figure 1). Furthermore, when HDT-ASCR and
alloSCT pts with a previous remission duration  12 months
prior to re-induction therapy were compared the estimated
3-year EFS was 79% for alloSCT and 36% for HDT-ASCR (P <
0.03). With relatively short follow-up, there was no differ-
ence in OS for these two groups.
Conclusion: The management of rel/ref FL remains a clini-
cally complex topic. In this exploratory analysis we demon-
strated that remission duration of  12 months prior to re-
induction chemotherapy is suggestive of inferior disease
control with HDT-ASCR. Longer follow-up is necessary to
determine the OS impact. Given the relatively unfavorable
pre-transplant characteristics of the alloSCT cohort, FL
appears to be exquisitely sensitive to an allogeneic effect.
Figure 1. EFS HDT-ASCR by Remission Duration to Re-induction.
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